NICE Backs First Immunotherapy for Resectable Gastric Cancer

Published Date: 16 May 2026

NICE has recommended durvalumab for NHS use in England as part of perioperative treatment for adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do Anatomy Atlases Reflect Social Inequalities?

2.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

QOL Maintained With Giredestrant Combo in Advanced BC

5.

Talc Powder Not Linked to Lung Cancer in Women


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot